Literature DB >> 11518373

Acute endovascular treatment by coil embolisation of ruptured intracranial aneurysms.

J V Byrne1.   

Abstract

Over 5 years, 317 consecutive patients were treated by coil embolisation within 30 days of aneurysm rupture. Neurological deteriorations were recorded in 35 patients during the first 48 h after treatment. In 21 patients these were due to procedural complications, which occurred in 31 procedures (9.8%). The timing of treatment relative to the last subarachnoid haemorrhage (SAH) was compared in patients treated after 0-2, 3-7, 8-14 and 15-30 days. No correlation was found in the incidence of such deteriorations and treatment periods, nor with patient's outcomes at 6 months. However, patients treated within 6 days of SAH had better outcomes than those treated later. Patients should, therefore, be treated as soon as possible after presentation since the technique appears less susceptible to the adverse effects of vasospasm in the 3-10 day period after SAH.

Entities:  

Mesh:

Year:  2001        PMID: 11518373      PMCID: PMC2503374     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  14 in total

1.  The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results.

Authors:  N F Kassell; J C Torner; E C Haley; J A Jane; H P Adams; G L Kongable
Journal:  J Neurosurg       Date:  1990-07       Impact factor: 5.115

2.  Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale.

Authors: 
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

3.  Endovascular treatment of the acutely ruptured intracranial aneurysm.

Authors:  D A Nichols
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

4.  Assessment of outcome after severe brain damage.

Authors:  B Jennett; M Bond
Journal:  Lancet       Date:  1975-03-01       Impact factor: 79.321

5.  Endovascular treatment of anterior communicating artery aneurysms using Guglielmi detachable coils.

Authors:  J Moret; L Pierot; A Boulin; L Castaings; A Rey
Journal:  Neuroradiology       Date:  1996-11       Impact factor: 2.804

6.  Endovascular treatment of posterior circulation aneurysms by electrothrombosis using electrically detachable coils.

Authors:  G Guglielmi; F Viñuela; G Duckwiler; J Dion; P Lylyk; A Berenstein; C Strother; V Graves; V Halbach; D Nichols
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

7.  Early treatment of ruptured aneurysms with Guglielmi detachable coils: effect on subsequent bleeding.

Authors:  V B Graves; C M Strother; T A Duff; J Perl
Journal:  Neurosurgery       Date:  1995-10       Impact factor: 4.654

8.  Endosaccular treatment of inoperable intracranial aneurysms with platinum coils.

Authors:  J V Byrne; C B Adams; R S Kerr; A J Molyneux
Journal:  Br J Neurosurg       Date:  1995       Impact factor: 1.596

9.  Total overall management and surgical outcome after aneurysmal subarachnoid haemorrhage in a defined population.

Authors:  G Edner; E Kågström; L Wallstedt
Journal:  Br J Neurosurg       Date:  1992       Impact factor: 1.596

10.  Unfavorable outcome following early surgical repair of ruptured cerebral aneurysms--a critical review of 238 patients.

Authors:  L M Auer
Journal:  Surg Neurol       Date:  1991-02
View more
  3 in total

1.  Endovascular surgery for ruptured aneurysms with vasospasm.

Authors:  A Kurata; S Suzuki; J Niki; H Ozawa; M Yamada; K Fujii; S Kan; T Kitahara; Y Miyasaka; T Ohmomo
Journal:  Interv Neuroradiol       Date:  2007-06-27       Impact factor: 1.610

2.  Coil embolization for intracranial aneurysms: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-01-01

Review 3.  Active bleeding from ruptured cerebral aneurysms during diagnostic angiography: emergency treatment.

Authors:  Joachim Klisch; Astrid Weyerbrock; Uwe Spetzger; Martin Schumacher
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.